Targeting the complexities of NASH
There are currently no approved treatments for nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) and diagnosis remains challenging. But studies show that fat and scar tissue can leave the liver, suggesting that NAFLD and NASH are reversible.
That's where we can help - Revvity offers a comprehensive portfolio of tools to enable further understanding of NASH pathophysiology, aid in the development of NASH diagnostic solutions for the assessment of NASH, help identify new therapeutic targets, and characterize novel drug therapies.
For research use only. Not for use in diagnostic procedures.
